Federal grants to Seattle Institute for Biomedical and Clinical Research
Seattle Institute for Biomedical and Clinical Research in Seattle, Washington received $59.8 million in federal grants from fiscal 2021 to 2025, across 44 awards. Its largest program was Aging Research, with $33.7 million. In fiscal 2025 it was awarded $10.9 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$59.8 million
- Awards44
- Awarded in FY 2025$10.9 million
- Largest award$7.8 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 21 | $6.7 million |
| FY 2022 | 23 | $15.6 million |
| FY 2023 | 23 | $15.1 million |
| FY 2024 | 19 | $11.5 million |
| FY 2025 | 20 | $10.9 million |
Programs that fund Seattle Institute for Biomedical and Clinical Research
| Program | Awards | Amount |
|---|---|---|
| Aging Research | 16 | $33.7 million |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 4 | $5.0 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 4 | $4.9 million |
| Military Medical Research and Development | 6 | $4.6 million |
| Cancer Cause and Prevention Research | 2 | $2.9 million |
| Drug Use and Addiction Research Programs | 1 | $1.9 million |
| Arthritis, Musculoskeletal and Skin Diseases Research | 2 | $1.6 million |
| Cardiovascular Diseases Research | 2 | $1.4 million |
| Mental Health Research Grants | 3 | $1.3 million |
| Cancer Treatment Research | 1 | $1.3 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 38 | $55.1 million |
| Department of Defense | 6 | $4.6 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Dementia with lewy bodies consortium | Aging Research | November 18, 2020 | $7.8 million |
| Defining the role of post-tbi sleep disruption in the development of cte and alzheimer's disease-related neuropathology - abstract mild traumatic brain injury (mtbi, concussion) has emerged as a risk factor for the development of neurodegenerative disorders such as alzheimer’s disease (AD) and chron | Aging Research | September 19, 2022 | $3.9 million |
| Role of astrocyte EAAT2/GLT1 failure in alzheimer's disease pathogenesis - astrocytes are ideally positioned to support neuronal/synaptic needs for trophic factors, metabolic homeostasis, and protection from toxicity. While reactive astrogliosis is a prominent feature of ad, this offers very limited | Aging Research | March 17, 2022 | $2.9 million |
| TDP-43 in alzheimer's disease - alzheimer’s disease, a severe progressive neurodegenerative disease of aging and the most common form of dementia, affects an estimated 30 million people worldwide. Pathologically, alzheimer’s disease is defined by the presence of both amyloid plaques comprised of the | Aging Research | August 25, 2021 | $2.6 million |
| On-tracc: a novel self-management intervention to improve long-term outcomes in veterans with a history of mild traumatic brain injury | Military Medical Research and Development | September 7, 2022 | $2.5 million |
| Targeting MSUT2 with small molecules to ameliorate pathological tau - abstract in frontotemporal lobar degeneration, alzheimer’s disease (AD) and related tauopathies, tau neuropathology correlates with severity of dementia. However, interventions for ad and ad related dementias (ADRDS) are largely l | Aging Research | August 16, 2023 | $2.2 million |
| Use of wearable sensors to improve the early diagnosis of dlb - project summary/abstract dementia with lewy bodies (DLB) is difficult to diagnose early in its disease course due to the overlap in initial symptoms with alzheimer's disease (AD). Many individuals with dlb therefore experience long dela | Aging Research | September 1, 2022 | $2.2 million |
| Protection from pathological tau by activation of the er unfolded protein response | Aging Research | February 8, 2021 | $2.1 million |
| Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency | Aging Research | May 6, 2021 | $2.0 million |
| Investigating the role of lipid metabolism in protein aggregation and neurodegenerative disease progression - project summary pathogenic protein aggregates are a hallmark neuropathologic finding in many neurodegenerative diseases. Most research has thus far focused on how these pathogenic aggregates | Extramural Research Programs in the Neurosciences and Neurological Disorders | November 26, 2020 | $2.0 million |
Questions people ask
How much federal grant money does Seattle Institute for Biomedical and Clinical Research get?
$59.8 million in 44 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Seattle Institute for Biomedical and Clinical Research the most?
The Department of Health and Human Services, with $55.1 million in 38 awards. The Department of Defense follow.
What is Seattle Institute for Biomedical and Clinical Research's largest federal grant?
$7.8 million under Aging Research, with its first action in the period on November 18, 2020. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Seattle Institute for Biomedical and Clinical Research?
Its largest are Aging Research, Extramural Research Programs in the Neurosciences and Neurological Disorders and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Seattle
- University of Washington
- Central Puget Sound Regional Transit Authority
- Fred Hutchinson Cancer Center
- King County Metro Transit
- Port of Seattle
- Seattle Children's Hospital
- Allen Institute
- Seattle Housing Authority
Largest federal grant recipients in Washington · Federal grants in Washington